Entire Portfolio
print

Composition of the portfolio as of June 30, 2015

Celgene   9.8%
Incyte   9.3%
Isis Pharmaceuticals   8.1%
Gilead   7.6%
Actelion   7.2%
Radius Health   6.3%
Agios Pharmaceuticals   5.3%
Vertex Pharmaceuticals   3.9%
Neurocrine Biosciences   3.7%
Medivation   3.5%
Alexion Pharmaceuticals   3.3%
Halozyme Therapeutics   3.3%
Receptos   3.0%
Alnylam Pharmaceuticals   2.8%
Regeneron Pharmaceuticals   2.4%
Novo Nordisk   2.3%
Novavax   2.2%
Swedish Orphan Biovitrum   1.8%
Tetraphase Pharmaceuticals   1.7%
Alder Biopharmaceuticals   1.5%
Puma Biotechnology   1.5%
Cempra   1.4%
PTC Therapeutics   1.4%
Clovis Oncology   1.3%
Tesaro   1.3%
Intercept Pharmaceuticals   1.0%
Infinity Pharmaceuticals   0.7%
Probiodrug   0.6%
Juno Therapeutics   0.6%
Kite Pharma   0.5%
Achillion Pharmaceuticals   0.3%
Theravance   0.1%
Theravance Biopharma   0.1%
     
     
Radius Health Warrants 23.04.2018   0.1%
Radius Health Warrants 19.02.2019   0.1%
Merck & Co Contingent Value Rights - ex Trius/Cubist   0.0%
     
Total Securities   CHF 3 927.5 mn
     
Other assets   CHF 141.8 mn
Other payables   CHF (33.2) mn
     
total shareholder's equity   CHF 4 036.1 mn
Treasury shares (in % of company) 1)   6.1%

 

1) Correspond to the total of all own shares held including the second trading line